Get the Stockscreener App
1.0839
0.00%
0.0061
After Hours:
1.08
-0.0039
-0.36%
Phio Pharmaceuticals Corp stock is traded at $1.0839, with a volume of 179.54K.
It is up +0.00% in the last 24 hours and down -8.40% over the past month.
Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.
See More
Previous Close:
$1.09
Open:
$1.09
24h Volume:
179.54K
Relative Volume:
0.67
Market Cap:
$12.59M
Revenue:
-
Net Income/Loss:
$-8.70M
P/E Ratio:
-0.7207
EPS:
-1.5039
Net Cash Flow:
$-7.99M
1W Performance:
+2.83%
1M Performance:
-8.40%
6M Performance:
-11.38%
1Y Performance:
-37.71%
1-Day Range:
$1.08
$1.1108
1-Week Range:
$1.06
$1.13
52-Week Range:
$0.8127
$4.1899
Phio Pharmaceuticals Corp Stock (PHIO) Company Profile
Name
Phio Pharmaceuticals Corp
Sector
Industry
Phone
(508) 767-3861
Address
411 SWEDELAND ROAD, KING OF PRUSSIA, MA
Compare PHIO vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHIO
Phio Pharmaceuticals Corp
|
1.0839 | 12.66M | 0 | -8.70M | -7.99M | -1.5039 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Phio Pharmaceuticals Corp Stock (PHIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-05-25 | Resumed | H.C. Wainwright | Buy |
| Aug-05-20 | Initiated | H.C. Wainwright | Buy |
Phio Pharmaceuticals Corp Stock (PHIO) Latest News
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series - TMX Newsfile
Skin cancer treatment PH-762: Phio live Q&A session May 28 - Stock Titan
PHIO Q1 2026 Earnings: EPS Misses Estimates as Research-Focused Biotech Maintains Development Pace - Newser
PHIO Stock Price, Quote & Chart | PHIO PHARMACEUTICALS CORP (NASDAQ:PHIO) - ChartMill
Phio Pharmaceuticals Announces "Innovations in Skin Cancer Treatment and Prevention" in a Fireside Chat with Force Family Office on Tuesday, May 19, 2026 - TMX Newsfile
Phio Pharmaceuticals (PHIO) Q1 2026 Results Miss Estimates — EPS $-0.34 vs $-0.24Product Mix - newser.com
Phio Pharmaceuticals Corp.Common Stock (NQ:PHIO) - FinancialContent
PHIO Should I Buy - Intellectia AI
TradingKey - TradingKey
Skin cancer drug hits 65% response; doctor, CEO to discuss what's next - Stock Titan
MSN Money - MSN
Why Phio Pharmaceuticals (PHIO) could be the turning point you've been waiting for (-0.87%) 2026-05-07Fast Rising Picks - newser.com
Phio Pharmaceuticals Corp. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Phio Pharmaceuticals (NASDAQ: PHIO) boosts PH-762 spending as Q1 2026 loss grows - Stock Titan
Phio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update - TMX Newsfile
Skin cancer drug trial wraps at Phio, FDA submission targets Q2 - Stock Titan
PHIO Q1'26 Earnings: EPS estimate is (0.23) USD - TradingView
Is Phio Pharmaceuticals (PHIO) stock forming a trend channel | Q4 2025: EPS Tops ViewsStrategic Review - Newser
Cancer drug developer Phio sets April 29 live Q&A on clinical progress - Stock Titan
Phio Pharmaceuticals (PHIO) Stock Resistance Rejection (Modest Decline) 2026-04-20Expert Breakout Alerts - Cổng thông tin điện tử tỉnh Lào Cai
Phio Pharmaceuticals Announces "Nobel Prize Winning Science Takes on Skin Cancer" in a Fireside Chat with Force Family Office on Wednesday, April 15, 2026 - TMX Newsfile
Phio Pharmaceuticals Announces Presentation at Centri Capital Conference on April 14, 2026 - TMX Newsfile
PHIO: RNA immunotherapy shows strong tumor clearance and safety, advancing to next clinical phase - TradingView
Phio Pharmaceuticals to Discuss 'Nobel Prize Winning Science' for Skin Cancer Treatment - National Today
EPS Watch: Is Phio Pharmaceuticals Corp a stock for growth or value investors2026 Trade Ideas & Reliable Volume Spike Trade Alerts - baoquankhu1.vn
User - The Chronicle-Journal
How do market conditions affect Phio Pharmaceuticals (PHIO) Stock | Price at $1.24, Up 2.48%Real Time Stock Idea Network - Newser
Form 8-KCurrent report - ADVFN
Ideas Watch: Does Phio Pharmaceuticals Corp have declining or rising EPSNew Guidance & Risk Controlled Swing Alerts - baoquankhu1.vn
Phio CEO heads to Nasdaq Marketsite for April 14 investor presentation - Stock Titan
Phio Pharmaceuticals Corp. Enters Material Definitive Agreement – SEC 8-K Filing Details April 8, 2026 - Minichart
Phio Pharmaceuticals Establishes New At-the-Market Equity Program - TipRanks
Phio Pharmaceuticals CorpEnters At The Market Offering Agreement With H.C. Wainwright On April 8, 2026 - TradingView
Phio Pharmaceuticals (NASDAQ: PHIO) launches $6.36M at-the-market stock plan - Stock Titan
Phio Pharmaceuticals (PHIO) files $6.36M ATM with H.C. Wainwright - Stock Titan
Pyramid Pharma Services Announces Drug Product Manufacturing Agreement for Phio Pharmaceuticals’ Lead Oncology - EIN News
What dividend growth rate does Phio Pharmaceuticals Corp offer2026 Chart Watch & Real-Time Stock Entry Alerts - baoquankhu1.vn
Will Phio Pharmaceuticals (PHIO) Stock Go Higher | Price at $1.25, Down 2.34%Free Stock Community - Newser
Profit Review: Is Phio Pharmaceuticals Corp on track to beat earningsSwing Trade & Detailed Earnings Play Alerts - baoquankhu1.vn
Phio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762 - TMX Newsfile
VIX Spike: Is Phio Pharmaceuticals Corp being accumulated by smart moneyQuarterly Risk Review & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
Phio Pharmaceuticals Corp Stock (PHIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Phio Pharmaceuticals Corp Stock (PHIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bitterman Robert J | Chairman, Pres. & CEO |
Dec 23 '25 |
Buy |
1.02 |
5,000 |
5,100 |
286,421 |
| Bitterman Robert J | Chairman, Pres. & CEO |
Nov 21 '25 |
Buy |
1.14 |
5,000 |
5,700 |
281,421 |
| Bitterman Robert J | Chairman, Pres. & CEO |
Nov 18 '25 |
Buy |
1.27 |
5,000 |
6,350 |
276,421 |
| Bitterman Robert J | Chairman, Pres & CEO |
Jun 10 '25 |
Buy |
2.42 |
2,000 |
4,840 |
27,149 |
| Ferrara Robert L | Director |
Jun 10 '25 |
Buy |
2.42 |
2,500 |
6,050 |
15,666 |
| Bitterman Robert J | Chairman, Pres & CEO |
Jun 09 '25 |
Buy |
2.75 |
1,500 |
4,125 |
25,149 |
1.49%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):